October 21, 2022 at 9:52 am

Plus Therapeutics Presents Promising Data from Clinical Trials; “Significant Clinical Interest” in Field

Clinical-stage pharmaceutical company, Plus Therapeutics (Nasdaq:PSTV), has presented data from two clinical trials evaluating its targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL) at the 35th Annual Congress of the European Association of Nuclear Medicine. The Company’s ReSPECT-GBM presentation was selected for inclusion in the opening Plenary Highlights Lecture, signaling significant clinical interest in the field.  Highlights 186RNL… [Read More]
October 20, 2022 at 10:48 pm

VolitionRx (VNRX) Shoots Up 23% As Company Signs Global Supply Agreement For Nu.Q Vet Cancer Test

VolitionRx (VNRX) shot up 23% after announcing that VNRX signed Global Supply Agreement for Nu.Q Vet Cancer Test. Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC commented: “The Nu.Q® Vet Cancer Test was developed with the goal of providing an accessible and affordable screening test to aid early detection. This supply agreement… [Read More]
October 19, 2022 at 9:36 pm

Sientra (SIEN) Plummets 37% as Company Proposes Public Offering

Sientra (SIEN) took major losses today, as the Company proposes a new public offering. Sientra’s share price fell to around $0.38, marking a new 52-week low. A couple details on the proposed offering are below: Each share of common stock (or common stock equivalent) will be sold with a warrant to purchase one share of… [Read More]
October 19, 2022 at 7:34 pm

MiMedx Launches First-Ever Human Placental Derived Surgical Recovery Product

Biologics company, MiMedx (Nasdaq: MDXG) has launched AXIOFILL™, a cost-effective surgical recovery product ideal for use in large, complex wounds and those of irregular geometries. AXIOFILL provides a distinct advantage over other particulate products and provides impressive clinical utility for physicians treating complex surgical wounds.  Highlights Mimedx’s product is the first and only human placental-derived… [Read More]
October 18, 2022 at 9:09 pm

Silvergate Capital (SI) Falls Almost 23% Behind Lagging Earnings and Delays

Silvergate Capital (SI) fell around 23% today, due to lagging earnings and the delay of its stablecoin.  The Company was hoping to release the stablecoin in 2022. “We’re certainly disappointed that it looks like we’re gonna miss our goal of launching it this year,” Alan Lane said at his company’s third-quarter earnings call, adding that the delay… [Read More]
October 18, 2022 at 12:11 pm

Quoin Pharmaceuticals: Share Price Soars More Than 30% on News of Second Clinical Trial

Clinical-stage specialty pharmaceutical company, Quoin Pharmaceuticals (Nasdaq: QNRX) plans to initiate a multicenter open label study of its lead product, QRX003, in Netherton Syndrome (NS) patients who are currently receiving systemic biologic therapy. A subset of NS patients is being treated off-label with systemic biologics that provide some symptomatic relief but do not address all… [Read More]
October 17, 2022 at 8:42 pm

Inovio Pharmaceuticals (INO) Jumps 17% on Positive Day in Healthcare

Inovio Pharmaceuticals (INO) jumped 17% today. INO hasn’t released any press releases today, but late last week the Company announced positive interim Phase 1/2 results for INO-3107 for the treatment of recurrent respiratory papillomatosis.  For more information on the trial update – see here: Press Release Inovio also could have been positively affected by the… [Read More]
October 17, 2022 at 2:34 pm

OraSure Technologies Lands $8.6M Contract to Develop Ebola Diagnostic

Diagnostic testing company, OraSure Technologies (Nasdaq: OSUR) has been awarded an $8.6 million contract by the Biomedical Advanced Research and Development Authority  (BARDA) to develop a second generation Ebola test. The test will be developed on the company’s OraQuick® platform and is expected to feature improved sensitivity, increased shelf life, new chemistry and more automation… [Read More]
October 17, 2022 at 9:18 am

ProMIS Neurosciences Closes Fully Subscribed Private Placement

Biotechnology company, ProMIS Neurosciences (Nasdaq: PMN), has closed a fully subscribed $7.4 million private placement. Investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Jeremy Sclar of WS Development and Dave Welch of 4-Good Ventures. Proceeds from the offering will be used to advance the company’s lead product candidate for Alzheimer’s disease (AD),… [Read More]